Radiation via Monoclonal Antibodies: Difference between revisions
(Created page with "<includeonly> {| class="wikitable" |- ! Property !! Information |- | Drug Name || Radiation via Monoclonal Antibodies |- | FDA Approval || Under research, not yet FDA-approved for general use |- | Used for || Glioblastoma (GBM) and potentially other high-grade glioma tumors |- | Clinical Trial Phase || Various phases, with some treatments in early clinical trials |- | Common Side Effects || Side effects vary depending on the specific monoclonal antibody and radioactive c...") |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{TreatmentInfo | |||
|drug_name=Radiation via Monoclonal Antibodies | |||
|FDA_approval=No | |||
|used_for=Glioblastoma and potentially other high-grade glioma tumors | |||
|clinical_trial_phase=Early to mid-stage clinical trials | |||
|common_side_effects=Varies; can include fatigue, headache, localized reactions at infusion site | |||
| | |OS_without=Standard treatments for GBM typically result in a median overall survival of 14-17 months | ||
| | |OS_with=Early trials show median survival times from 56 weeks for recurrent GBM to up to 24.9 months in certain cohorts | ||
|PFS_without=Median progression-free survival with standard treatments is about 6-9 months for GBM | |||
|PFS_with=Some studies report mean progression-free survival up to 17.2 months, compared to 4-10 months for other treatments | |||
|- | |usefulness_rating=3 | ||
|usefulness_explanation=Shows promise for targeted radiation delivery to tumor cells with potential for sparing normal tissue and reducing side effects, but more research is needed for a definitive assessment | |||
| | |toxicity_level=3 | ||
|toxicity_explanation=Potential risks are present and may be comparable to or slightly less than traditional treatments, with concerns about toxicity under investigation | |||
| | |book_text=Radiation therapy via monoclonal antibodies introduces a targeted approach to delivering radiation to glioblastoma cells. This method involves attaching radioactive isotopes, such as iodine-131, to monoclonal antibodies that target specific antigens present on tumor cells but not on normal brain cells. The approach aims to maximize the therapeutic impact on the tumor while minimizing exposure and damage to surrounding healthy brain tissue. Duke University has been a pioneer in applying this technique. The major challenges include overcoming the blood-brain barrier and navigating the immunosuppressive tumor microenvironment. Early clinical trials have shown promising outcomes, with certain patient cohorts experiencing extended median survival times. However, the effectiveness and safety of this treatment are still under active investigation, highlighting the need for ongoing research and clinical trials to fully understand its potential and limitations. | ||
}} | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
Latest revision as of 00:29, 30 March 2024
From Ben Williams Book: Radiation therapy via monoclonal antibodies introduces a targeted approach to delivering radiation to glioblastoma cells. This method involves attaching radioactive isotopes, such as iodine-131, to monoclonal antibodies that target specific antigens present on tumor cells but not on normal brain cells. The approach aims to maximize the therapeutic impact on the tumor while minimizing exposure and damage to surrounding healthy brain tissue. Duke University has been a pioneer in applying this technique. The major challenges include overcoming the blood-brain barrier and navigating the immunosuppressive tumor microenvironment. Early clinical trials have shown promising outcomes, with certain patient cohorts experiencing extended median survival times. However, the effectiveness and safety of this treatment are still under active investigation, highlighting the need for ongoing research and clinical trials to fully understand its potential and limitations.Property "Has original text" (as page type) with input value "Radiation therapy via monoclonal antibodies introduces a targeted approach to delivering radiation to glioblastoma cells. This method involves attaching radioactive isotopes, such as iodine-131, to monoclonal antibodies that target specific antigens present on tumor cells but not on normal brain cells. The approach aims to maximize the therapeutic impact on the tumor while minimizing exposure and damage to surrounding healthy brain tissue. Duke University has been a pioneer in applying this technique. The major challenges include overcoming the blood-brain barrier and navigating the immunosuppressive tumor microenvironment. Early clinical trials have shown promising outcomes, with certain patient cohorts experiencing extended median survival times. However, the effectiveness and safety of this treatment are still under active investigation, highlighting the need for ongoing research and clinical trials to fully understand its potential and limitations." contains invalid characters or is incomplete and therefore can cause unexpected results during a query or annotation process.
